Zandbergen Fokko, Plutzky Jorge
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 77 Avenue Louis Pasteur, NRB 742, Boston, MA 02115, USA.
Biochim Biophys Acta. 2007 Aug;1771(8):972-82. doi: 10.1016/j.bbalip.2007.04.021. Epub 2007 May 21.
Peroxisome proliferator-activated receptor (PPAR)alpha is a nuclear receptor activated by natural ligands such as fatty acids as well as by synthetic ligands such as fibrates currently used to treat dyslipidemia. PPARalpha regulates the expression of genes encoding proteins that are involved in lipid metabolism, fatty acid oxidation, and glucose homeostasis, thereby improving markers for atherosclerosis and insulin resistance. In addition, PPARalpha exerts anti-inflammatory effects both in the vascular wall and the liver. Here we provide an overview of the mechanisms through which PPARalpha affects the initiation and progression of atherosclerosis, with emphasis on the modulation of atherosclerosis-associated inflammatory responses. PPARalpha activation interferes with early steps in atherosclerosis by reducing leukocyte adhesion to activated endothelial cells of the arterial vessel wall and inhibiting subsequent transendothelial leukocyte migration. In later stages of atherosclerosis, evidence suggests activation of PPARalpha inhibits the formation of macrophage foam cells by regulating expression of genes involved in reverse cholesterol transport, formation of reactive oxygen species (ROS), and associated lipoprotein oxidative modification among others. Furthermore, PPARalpha may increase the stability of atherosclerotic plaques and limit plaque thrombogenicity. These various effects may be linked to the generation of PPARalpha ligands by endogenous mechanisms of lipoprotein metabolism. In spite of this dataset, other reports implicate PPARalpha in responses such as hypertension and diabetic cardiomyopathy. Although some clinical trials data with fibrates suggest that fibrates may decrease cardiovascular events, other studies have been less clear, in terms of benefit. Independent of the clinical effects of currently used drugs purported to achieve PPARalpha, extensive data establish the importance of PPARalpha in the transcriptional regulation of lipid metabolism, atherosclerosis, and inflammation.
过氧化物酶体增殖物激活受体(PPAR)α是一种核受体,可被脂肪酸等天然配体以及目前用于治疗血脂异常的贝特类等合成配体激活。PPARα调节参与脂质代谢、脂肪酸氧化和葡萄糖稳态的蛋白质编码基因的表达,从而改善动脉粥样硬化和胰岛素抵抗的标志物。此外,PPARα在血管壁和肝脏中均发挥抗炎作用。在此,我们概述了PPARα影响动脉粥样硬化发生和发展的机制,重点是对动脉粥样硬化相关炎症反应的调节。PPARα激活通过减少白细胞与动脉血管壁活化内皮细胞的黏附并抑制随后的跨内皮白细胞迁移,干扰动脉粥样硬化的早期步骤。在动脉粥样硬化的后期阶段,有证据表明PPARα激活通过调节参与逆向胆固醇转运、活性氧(ROS)形成以及相关脂蛋白氧化修饰等基因的表达,抑制巨噬细胞泡沫细胞的形成。此外,PPARα可能增加动脉粥样硬化斑块的稳定性并限制斑块的血栓形成性。这些不同的作用可能与脂蛋白代谢的内源性机制产生PPARα配体有关。尽管有这些数据,但其他报告表明PPARα参与高血压和糖尿病性心肌病等反应。尽管一些使用贝特类药物的临床试验数据表明贝特类药物可能减少心血管事件,但其他研究在益处方面并不那么明确。无论目前声称可实现PPARα激活的药物的临床效果如何,大量数据证实了PPARα在脂质代谢、动脉粥样硬化和炎症的转录调节中的重要性。